Neurocrine Biosciences (NBIX) Enterprise Value (2016 - 2021)
Historic Enterprise Value for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to -$765.9 million.
- Neurocrine Biosciences' Enterprise Value rose 1892.66% to -$765.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was -$765.9 million, marking a year-over-year increase of 1892.66%. This contributed to the annual value of -$804.2 million for FY2020, which is 1994.03% down from last year.
- As of Q3 2021, Neurocrine Biosciences' Enterprise Value stood at -$765.9 million, which was up 1892.66% from -$884.9 million recorded in Q2 2021.
- In the past 5 years, Neurocrine Biosciences' Enterprise Value ranged from a high of -$235.6 million in Q1 2017 and a low of -$948.3 million during Q2 2020
- Over the past 5 years, Neurocrine Biosciences' median Enterprise Value value was -$650.9 million (recorded in 2018), while the average stood at -$659.0 million.
- In the last 5 years, Neurocrine Biosciences' Enterprise Value surged by 3825.29% in 2017 and then tumbled by 9546.61% in 2018.
- Over the past 5 years, Neurocrine Biosciences' Enterprise Value (Quarter) stood at -$515.9 million in 2017, then fell by 26.16% to -$650.9 million in 2018, then fell by 3.01% to -$670.5 million in 2019, then fell by 19.94% to -$804.2 million in 2020, then increased by 4.76% to -$765.9 million in 2021.
- Its last three reported values are -$765.9 million in Q3 2021, -$884.9 million for Q2 2021, and -$873.7 million during Q1 2021.